In today’s highly regulated pharmaceutical environment, data integrity has become one of the most critical aspects of Good Manufacturing Practices (GMP). Regulatory authorities such as the U.S. FDA, MHRA, EMA, WHO, and PIC/S continue to increase their focus on ensuring that pharmaceutical data is accurate, complete, reliable, and protected throughout its lifecycle.
Data integrity failures can lead to FDA warning letters, import bans, product recalls, regulatory sanctions, and significant damage to a company’s reputation. As regulatory expectations evolve, pharmaceutical professionals must stay informed about the latest guidance and compliance requirements.
To help industry professionals navigate these challenges, a comprehensive live training webinar titled “GMP Data Integrity Best Practices and Regulatory Expectations for the Pharmaceutical Industry” is scheduled for Wednesday, June 10, 2026, featuring renowned industry expert Peter Calcott, Ph.D.
Why Data Integrity Is More Important Than Ever
Data serves as the foundation for every decision made in pharmaceutical manufacturing, quality control, laboratory testing, validation, and regulatory submissions. When data cannot be trusted, regulators cannot trust the quality, safety, or efficacy of pharmaceutical products.
Recent inspections conducted by the FDA and MHRA have revealed numerous data integrity concerns, including:
- Missing or incomplete records
- Backdated documentation
- Manipulated laboratory results
- Disabled audit trails
- Shared user accounts
- Unauthorized data modifications
- Failure to investigate discrepancies
Such findings often result in severe regulatory consequences and costly remediation efforts.
About the Webinar
This instructor-led training session provides a practical and comprehensive review of current global data integrity requirements and regulatory expectations.
Webinar Details
Title: GMP Data Integrity Best Practices and Regulatory Expectations for the Pharmaceutical Industry
Date: Wednesday, June 10, 2026
Time: 10:30 AM – 12:30 PM ET (New York)
Instructor: Peter Calcott, Ph.D.
The webinar is designed to help pharmaceutical organizations establish, strengthen, and maintain robust data integrity programs that withstand regulatory scrutiny.
Key Learning Benefits
Participants will gain valuable insights into:
Understanding MHRA Data Integrity Guidance
The training provides a detailed review of MHRA GMP Data Integrity definitions and guidance documents, helping attendees understand regulatory expectations and inspection trends.
Reviewing FDA Data Integrity Principles
Attendees will learn how FDA guidance applies to pharmaceutical operations and how inspectors assess compliance during audits and inspections.
Applying Quality Risk Management
The webinar explains how ICH Q9 Quality Risk Management principles can be used to identify vulnerabilities and implement preventive controls.
Detecting Data Integrity Issues
Participants will learn how to recognize warning signs and indicators of potential data integrity failures before they become major compliance problems.
Understanding Intentional vs. Unintentional Failures
Not all data integrity issues arise from misconduct. The course explores how to distinguish between system weaknesses, human error, and intentional falsification.
Developing Effective Remediation Strategies
Organizations will learn practical methods to investigate root causes, implement corrective actions, and establish sustainable compliance programs.
Regulatory Frameworks Covered
One of the webinar’s major strengths is its comprehensive review of international regulatory expectations.
Topics include:
European Union Regulations
- EudraLex Volume 1
- EudraLex Volume 2
- EudraLex Volume 3
- EudraLex Volume 4
- EudraLex Volume 9
United States Regulations
- 21 CFR Part 210
- 21 CFR Part 211
- 21 CFR 600 Series
MHRA Guidance
- MHRA Data Integrity Guidance 2015
- MHRA Data Integrity Guidance 2016
- MHRA Data Integrity Guidance 2018 Updates
FDA Guidance
- FDA Data Integrity and Compliance with cGMP Guidance
International Standards
- EMA Guidance
- WHO Guidance
- PIC/S Guidance
- ICH Q9 Quality Risk Management
This global perspective is especially valuable for organizations operating across multiple regulatory jurisdictions.
Webinar Agenda
10:15 AM – Login Period
Participants can access the training platform and prepare for the session.
10:30 AM – Introduction
Overview of data integrity principles and current regulatory focus areas.
10:40 AM – Core Data Integrity Concepts
Topics include:
- What is data integrity?
- Business and regulatory impact
- Common failure points
- Detection methods
- Intentional versus unintentional violations
11:30 AM – Break
A brief 10-minute break.
11:40 AM – Advanced Compliance Strategies
Discussion topics include:
- Root cause analysis
- Failure investigations
- MHRA expectations
- FDA enforcement trends
- Regulatory warning letters
- Prevention strategies
- Building a compliance culture
12:30 PM – Live Q&A Session
Attendees can interact directly with the instructor and discuss real-world compliance challenges.
Who Should Attend?
The webinar is ideal for professionals involved in pharmaceutical quality systems and regulatory compliance, including:
Quality Assurance Professionals
QA teams responsible for ensuring GMP compliance and maintaining quality systems.
Quality Control Personnel
Laboratory analysts, supervisors, and managers who generate and review GMP data.
Regulatory Affairs Specialists
Professionals preparing submissions and managing regulatory interactions.
Process Development Scientists
Individuals involved in process optimization and product development.
Supply Chain and Logistics Managers
Professionals responsible for maintaining data accuracy throughout the supply chain.
IT and Computer System Specialists
Personnel managing electronic systems, audit trails, and data security controls.
Engineering Teams
Engineers involved in validation, automation, and manufacturing systems.
Senior Management
Executives responsible for governance, compliance culture, and regulatory readiness.
Project Managers
Professionals managing Chemistry, Manufacturing, and Controls (CMC) activities and cross-functional projects.
What Participants Receive
Registered attendees will receive:
- Presentation slides
- Training certificate
- Practical compliance guidance
- Regulatory insights from an industry expert
- Access to live Q&A discussions
These resources can support both individual professional development and organizational training programs.
Why Organizations Should Invest in Data Integrity Training
Regulatory agencies increasingly expect pharmaceutical companies to demonstrate a proactive approach to data integrity.
Training entire teams together offers several advantages:
- Consistent understanding of requirements
- Improved cross-functional communication
- Better compliance culture
- Reduced inspection risk
- Stronger quality systems
- Enhanced patient safety protection
Organizations that invest in data integrity education are better prepared to detect vulnerabilities, prevent compliance failures, and maintain regulatory confidence.
Conclusion
Data integrity remains one of the most scrutinized areas during pharmaceutical inspections worldwide. With evolving guidance from the FDA, MHRA, EMA, WHO, and PIC/S, staying informed about current expectations is essential for maintaining GMP compliance.
The “GMP Data Integrity Best Practices and Regulatory Expectations for the Pharmaceutical Industry” webinar provides pharmaceutical professionals with practical knowledge, regulatory insights, and risk management strategies necessary to build strong data integrity programs. Whether your organization is establishing a new compliance framework or enhancing existing systems, this training offers valuable tools to support long-term regulatory success and protect patient safety.
Recommended Products
